Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H32O3 |
Molecular Weight | 332.477 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@@]4([H])CC(=O)\C(C[C@]34C)=C/O
InChI
InChIKey=ICMWWNHDUZJFDW-DHODBPELSA-N
InChI=1S/C21H32O3/c1-19-11-13(12-22)18(23)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,22,24H,4-11H2,1-3H3/b13-12-/t14-,15+,16-,17-,19-,20-,21-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11440282Curator's Comment: Description was created based on several sources, includinghttp://medapharma.us/products/pi/Anadrol-50_PI.pdf
https://www.ncbi.nlm.nih.gov/pubmed/11365560
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11440282
Curator's Comment: Description was created based on several sources, includinghttp://medapharma.us/products/pi/Anadrol-50_PI.pdf
https://www.ncbi.nlm.nih.gov/pubmed/11365560
Oxymetholone (17beta-hydroxy-2-[hydroxymethylene]-17-methyl-5alpha-androstan-3-one) is a 17alpha-alkylated anabolic-androgenic steroid and a synthetic derivative of testosterone. It has been approved by the US Food and Drug Administration for the treatment of anemias caused by deficient red cell production. Acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond. Drug interactions exist with cimetidine, paroxetine, and haloperidol, but are not expected with indinavir, ritonavir, clarithromycin, or itraconazole.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10217522
Curator's Comment: Known to be CNS active in rats. Human data not available.
Originator
Sources: http://pubs.acs.org/doi/abs/10.1021/ja01511a040
Curator's Comment: Ringold et al, 1959 (Syntex SA)
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6539197 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ANADROL-50 Approved UseAnadrol®-50 Tablets is indicated in the treatment of anemias caused by deficient red cell production. Acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs often respond. Anadrol®-50 Tablets should not replace other supportive measures such as transfusion, correction of iron, folic acid, vitamin B12 or pyridoxine deficiency, antibacterial therapy and the appropriate use of corticosteroids. Launch Date1972 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
unlikely [IC50 206 uM] | ||||
unlikely [IC50 300 uM] | ||||
Page: 4.0 |
unlikely [IC50 383 uM] | |||
unlikely [IC50 67.5 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 4.0 |
no |
PubMed
Title | Date | PubMed |
---|---|---|
Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. | 1972 Dec 16 |
|
Androgen-induced hepatoma. | 1975 Feb 22 |
|
Carcinoma of the breast. Occurence after treatment with melphalan for multiple myeloma. | 1976 Oct 4 |
|
Nonfatal methazolamide-induced aplastic anemia. | 1978 Jul |
|
Pure red blood cell aplasia complicating chronic lymphatic leukemia. | 1983 Sep-Oct |
|
Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. | 2004 Nov |
|
Characterization of spontaneous and chemically induced cardiac lesions in rodent model systems: the national toxicology program experience. | 2005 |
|
Direct and indirect effects of androgens on survival of hematopoietic progenitor cells in vitro. | 2005 Jun |
|
Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. | 2005 May |
|
Oxymetholone ameliorates insulin sensitivity in maintenance hemodialysis patients: a randomized controlled trial. | 2009 Apr |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
|
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs. | 2015 Jun |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://medapharma.us/products/pi/Anadrol-50_PI.pdf
The recommended daily dose in children and adults is 1-5 mg/kg of body weight per day.
The usual effective dose is 1-2 mg/kg/day but higher doses may be required, and the dose
should be individualized. Response is not often immediate, and a minimum trial of three to
six months should be given. Following remission, some patients may be maintained without
the drug; others may be maintained on an established lower daily dosage. A continued
maintenance dose is usually necessary in patients with congenital aplastic anemia.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15953861
0.1 to 10 uM oxymetholone tested on normal CD34+ cells
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C243
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
||
|
DEA NO. |
4000
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
||
|
WIKIPEDIA |
Designer-drugs-Oxymetholone
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
||
|
WHO-VATC |
QA14AA05
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
||
|
LIVERTOX |
727
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
||
|
WHO-ATC |
A14AA05
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
||
|
NCI_THESAURUS |
C2360
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1200585
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | |||
|
D010110
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | |||
|
L76T0ZCA8K
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | |||
|
100000083305
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | |||
|
3374
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | |||
|
26198
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | |||
|
78964-17-7
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
ALTERNATIVE | |||
|
7864
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | |||
|
1487007
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | |||
|
OXYMETHOLONE
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | |||
|
C723
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | |||
|
7813
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | RxNorm | ||
|
2033
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | |||
|
SUB09568MIG
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | |||
|
5281034
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | |||
|
1022
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | |||
|
m8336
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB06412
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | |||
|
434-07-1
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | |||
|
DTXSID5023794
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY | |||
|
207-098-6
Created by
admin on Fri Dec 15 16:10:54 GMT 2023 , Edited by admin on Fri Dec 15 16:10:54 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)